Core A: Administrative CoreThe objectives of the Administrative Core is to provide overall fiscal and scientific support for the ProgramProject grant. The Administrative Core interacts directly with each project and core in support of this goal.The administrative functions of this Program Project involve the coordination and integration of the entireproposal. The Core maintains overall fiscal, as well as scientific responsibility and provides general day today core support for the Program. Dr. Robert T. Dorr serves as the Principal Investigator of this ProgramProject. He is a clinical pharmacist and cancer pharmacologist whose research interests focus on preclinicaldrug discovery and early clincial trial drug evaluation.The Administrative Core works closely with the Cancer Center Business Office accountants to ensure thattimely budget updates are provided to all investigators. The Administrative Core initiates subcontracts withother institutions. They approve and allocate funds to support consultants travel and accommodations forthe grant. They work with the investigators, the Cancer Center Business Office accountants, and theUniversity of Arizona Sponsored Projects staff to ensure appropriate expenditure of grant funds.The Administrative Core schedules monthly meeting for the investigators to facilitate communication andresearch collaboration. The various meetings include faculty and staff, outside consultants and the InternalData and Safety Monitoring Committee. These meetings and/or teleconferences are essential to ensuringcommunication and collaboration. Core administrative staff is responsible for reporting activity to theUniversity of Arizona's IRB and the NIH. They also serve as an administrative and research resource to theproject and core investigators and staff.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Arizona
United States
Zip Code
Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35
Barrett, Harrison H; Alberts, David S; Woolfenden, James M et al. (2016) Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) 3:023502
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Malm, Scott W; Hanke, Neale T; Gill, Alexander et al. (2015) The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res 34:31
Landowski, Terry H; Gard, Jaime; Pond, Erika et al. (2014) Targeting integrin ?6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther 13:1558-66
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Dragovich, T; Laheru, D; Dayyani, F et al. (2014) Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 74:379-87
Exley, Mark A; Hand, Laura; O'Shea, Donal et al. (2014) Interplay between the immune system and adipose tissue in obesity. J Endocrinol 223:R41-8
Zhang, Xiaomeng; Pagel, Mark D; Baker, Amanda F et al. (2014) Reproducibility of magnetic resonance perfusion imaging. PLoS One 9:e89797

Showing the most recent 10 out of 314 publications